<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2017012932276N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-06-27</date_registration>
      <primary_sponsor>iran univercity of medical science</primary_sponsor>
      <public_title>The effect of regulating the flow rate of cardiopulmonary bypass pump based on lean body mass index on mixed venous blood oxygen and arterial blood lactat level among patients with abnormal range of body mass index</public_title>
      <acronym></acronym>
      <scientific_title>The effect of regulating the flow rate of cardiopulmonary bypass pump based on lean body mass index on mixed venous blood oxygen and arterial blood lactat level among patients with abnormal range of body mass index</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-05-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>152</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/25181</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Other design features: Allocation of samples in the form of blocks Random can be done using a computer.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Heart disease.</hc_freetext>
      <i_freetext>Intervention 1: In this study, in the intervention group, patients with BMI over 25, obtained number from lean body mass will be multiplied by 2.4 and according to it pump flow will be arranged in cardiopulmonary bypass machine. After anesthesia, first blood sample will be taken using 2 ml heparinized syringe from radial artery and the venous blood sample will be taken from the central venous. Second blood sample will be obtained after cross- clamped of the aorta and cardioplegia induction. During rewarming and after declamping in temperature between 35-37 degree, third sample will be taken from oxygenator arterial line sample and venous reservoir entrance, respectively.   In case of long surgery procedures, sampling will be repeated every half an hour. Finally, based on gained samples, measuring arterial lactate level   and mixed venous oxygen saturation will be done. Intervention 2: In this study, in the control   group, patients with BMI over 25, obtained number from bodr sueface area will be multiplied by 2.4 and according to it pump flow will be arranged in cardiopulmonary bypass machine. After anesthesia, first blood sample will be taken using 2 ml heparinized syringe from radial artery and the venous blood sample will be taken from the central venous. Second blood sample will be obtained after cross- clamped of the aorta and cardioplegia induction. During rewarming and after declamping in temperature between 35-37 degree, third sample will be taken from oxygenator arterial line sample and venous reservoir entrance, respectively.   In case of long surgery procedures, sampling will be repeated every half an hour. Finally, based on gained samples, measuring arterial lactate level   and mixed venous oxygen saturation will be done.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Parvin Vahid</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing, Iran University of Medical Sciences, Rashid Yaasemi street, Valiasr street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1996713883</zip>
        <telephone>+98 21 8888 2886</telephone>
        <email>vahid .p@tak.iums.ac.ir</email>
        <affiliation>Iran University of Medical Science</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>dr Tahereh Najafi Ghezeljeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing, Iran University of Medical Sciences, Rasheed Yaasemi street, Valiasr street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1996713883</zip>
        <telephone>+98 21 8888 2885</telephone>
        <email>najafi.t@iums.ac.ir</email>
        <affiliation>School of nursing &amp; midwifery of Iran University of Medical Science</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria:&#13;
 1، Older than 18 years old 2، body mass index of between 25-35  3،open heart surgery with the use of cardiopulmonary bypass  4،not having   disorder in kidney, lung, liver and cerebral and  treatment-resistant hypertension 5, left ventricular ejection fraction more than 30% 6، patients with bilateral carotid artery stenosis  greater than 50% or unilateral carotid stenosis greater than 70%  7,patients elective open heart surgery &#13;
 exclusion criteria from the study:&#13;
 1 , any event that affect the normal process of open heart surgery include cardiopulmonary bypass requirement though surgery,  persistent decline of blood pressure  through cardiopulmonary bypass that not respond to Inotropic drug  2, death  3, aortic clamping time over 100 minutes 4, temperature reduction below 28 degree during operation for any reason the surgeon decide to catch a lower temperature than 28 degree</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I25.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Atherosclerotic cardiovascular disease, so described</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In this study, in the intervention group, patients with BMI over 25, obtained number from lean body mass will be multiplied by 2.4 and according to it pump flow will be arranged in cardiopulmonary bypass machine. After anesthesia, first blood sample will be taken using 2 ml heparinized syringe from radial artery and the venous blood sample will be taken from the central venous. Second blood sample will be obtained after cross- clamped of the aorta and cardioplegia induction. During rewarming and after declamping in temperature between 35-37 degree, third sample will be taken from oxygenator arterial line sample and venous reservoir entrance, respectively.   In case of long surgery procedures, sampling will be repeated every half an hour. Finally, based on gained samples, measuring arterial lactate level   and mixed venous oxygen saturation will be done.</i_keyword>
      <i_keyword>In this study, in the control   group, patients with BMI over 25, obtained number from bodr sueface area will be multiplied by 2.4 and according to it pump flow will be arranged in cardiopulmonary bypass machine. After anesthesia, first blood sample will be taken using 2 ml heparinized syringe from radial artery and the venous blood sample will be taken from the central venous. Second blood sample will be obtained after cross- clamped of the aorta and cardioplegia induction. During rewarming and after declamping in temperature between 35-37 degree, third sample will be taken from oxygenator arterial line sample and venous reservoir entrance, respectively.   In case of long surgery procedures, sampling will be repeated every half an hour. Finally, based on gained samples, measuring arterial lactate level   and mixed venous oxygen saturation will be done</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>On mixed venous oxygen saturation. Timepoint: after anesthesia,during cardiiopulmonary bypass,after cardiopulmonary bypass. Method of measurement: content of each gas in arterial blood Under the pressure of eac gas.</prim_outcome>
      <prim_outcome>Arterial blood lactate. Timepoint: after anesthesia,during cardiiopulmonary bypass,after cardiopulmonary bypass. Method of measurement: arterial blood sample.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>O2 consumption. Timepoint: during cardiopulmonary bypass. Method of measurement: content of each gas in venous blood Under the pressure of eac gas and  pump flow rate.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>iran univercity of medical science</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-03-04</approval_date>
        <contact_name>Ethics Committee of Iran Univercity of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Shahid Hemmat highway, Tehran, Iran Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
